<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824226</url>
  </required_header>
  <id_info>
    <org_study_id>UT296</org_study_id>
    <nct_id>NCT00824226</nct_id>
  </id_info>
  <brief_title>Magnesium Treatment in Hypoparathyroidism</brief_title>
  <official_title>Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: supplementary magnesium may influence the blood calcium level in treated
      hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day)
      for 3 weeks. Calcium and other relevant blood parameters will be measured before the
      treatment, at the end of treatment and 2 weeks after stopping treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calcium level at the end of magnesium treatment compared to pretreatment level</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium level after stopping treatment compared to the level at the end of magnesium treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Hypoparathyroidism</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>magnesium</intervention_name>
    <description>magnesium 350 mg tablets once a day for 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary or secondary hypoparathyroidism

          -  treatment with calcium plus vitamin D analogue

          -  ionized calcium 1,0-1,29 mmol/L

          -  magnesium level 0,7-1,05 mmol/L

          -  TSH 0.1- 10 imU/L

        Exclusion Criteria:

          -  any other disease known to influence plasma Ca level

          -  pregnancy

          -  creatinine &gt; 150 microM/L

          -  patient has used supplementary magnesium within 2 previous months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vallo Volke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu, Institute of Physiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Vallo Volke</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>primary hypoparathyroidism</keyword>
  <keyword>secondary hypoparathyroidism</keyword>
  <keyword>magnesium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

